QURE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages QURE Investors with Losses to Contact the Firm

Core Viewpoint - A securities fraud class action lawsuit has been filed against uniQure N.V. for allegedly misleading investors regarding its Huntington's disease gene therapy drug, AMT-130, during the class period from September 24, 2025, to October 31, 2025 [1] Company Overview - uniQure N.V. is a biotechnology company focused on developing gene therapies for rare diseases, with AMT-130 as its leading drug candidate aimed at slowing the progression of Huntington's disease [1] - The company faced significant scrutiny due to alleged material misstatements and omissions related to its clinical trials and the timeline for its Biologics License Application (BLA) submission to the FDA [1] Legal Proceedings - The lawsuit, titled Scocco v. uniQure N.V., was filed in the United States District Court for the Southern District of New York [1] - Investors who purchased shares during the class period are encouraged to contact Kessler Topaz Meltzer & Check, LLP for recovery options, with a deadline to seek lead plaintiff status set for April 13, 2026 [1] Allegations - The complaint alleges that uniQure misrepresented the approval status of its Pivotal Study design by the FDA and downplayed the likelihood of delays in the BLA submission timeline [1] - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the data from its Phase I/II studies were adequate for BLA submission, leading to a significant drop in share price by over 49% [1]